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Abstract Introduction: The prevalence of patients with ‘borderline’ levels of cardiovascular risk factors has been
rarely investigated, being often reported in studies evaluating abnormal values of these parameters. The
BORDERLINE study represents a pilot experience to primarily identify the prevalence of ‘high-normal’
conditions, such as pre-hypertension, lipid and glucose levels in the upper range of normality in the setting of
general practice in Italy.
Aim: The aim of this study was to evaluate the prevalence of patients with ‘borderline’ values of cardio-
vascular risk factors in Italy.
Methods: Involved physicians were asked to evaluate the first 20 outpatients, consecutively seen in June
2009. Data were collected in a study-designed case-report form, in which physicians identified thresholds
rather than reported absolute values of several clinical parameters. High-normal values were defined as
follows: blood pressure (BP) 130–140/85–90mmHg; total cholesterol 180–200mg/dL; low-density lipo-
protein cholesterol (LDL-C) 130–150mg/dL; high-density lipoprotein cholesterol (HDL-C) 30–40mg/dL in
males and 40–50mg/dL in females; triglycerides 130–150mg/dL and fasting glucose 100–110mg/dL.
Results: Fifty-three Italian physicians provided valuable clinical data on 826 individual outpatients, among
which 692 (83.7%, 377 women, mean age 60.9– 13.2 years, body mass index 26.6– 5.0 kg/m2) were included
in the present analysis. Prevalence of borderline values of systolic BP and total cholesterol levels were at least
comparable with those in the normal limits of the corresponding parameters, whereas prevalence of bor-
derline diastolic BP, LDL-C, HDL-C, triglycerides and fasting glucose levels was significantly lower than
that of normal values, but higher than that of abnormal values of the corresponding parameters.
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Conclusions: Using this sample of healthy subjects in the setting of general practice in Italy, our results
demonstrated a relatively high prevalence of borderline values of cardiovascular risk factors, which was at
least comparable with that of normal, but significantly higher than that of abnormal thresholds. These
preliminary findings may prompt more extensive investigations in the area of ‘borderline’ cardiovascular
risk. This informationmay, in fact, potentially enable the design ofmore effective prevention strategies in the
future to limit the burden of cardiovascular disease in the general population in Italy.
Received for publication 4 March 2011; accepted for publication 20 April 2011.
Keywords: borderline risk, high-normal risk, cardiovascular prevention, global cardiovascular risk,
blood pressure, cholesterol, glucose.
Introduction
Cardiovascular disease still represents the leading cause of
morbidity and mortality worldwide.[1] Thus, strategies for
cardiovascular disease prevention have progressively become a
priority in the public agenda of national healthcare systems,
mostly in Western countries.[2] These strategies, however, have
failed to substantially reduce cardiovascular morbidity and the
overall burden of cardiovascular disease.[2] This persistent gap
between objective and attained results in terms of cardiovascu-
lar disease preventionmay be due to several factors. Among these,
the continuous increase of major cardiovascular risk factors,
particularly arterial hypertension, hypercholesterolaemia, obesity,
metabolic syndrome and diabetes mellitus, as well as the persis-
tently high prevalence of unfavourable lifestyle habits (smoking,
sedentary habits, high dietary intake) are largely responsible for
the global burden of cardiovascular disease.[3]
During the last decade, international scientific societies have
focused their attention on the clinical management of con-
comitant cardiovascular risk factors, proposing an integrated
approach, in order to reduce the global cardiovascular risk of
individual patients, rather than absolute levels of individual
risk factors.[4] Results from large observational studies have
demonstrated the efficacy of such an approach only in those
patients at high or very high cardiovascular risk profile.[5-8]
Modern medicine has, in fact, succeeded in significantly reduc-
ing mortality in the acute phase of cardiovascular disease and
considerably ameliorated cardiovascular and renal outcomes.
However, this strategy, based on intensive and integrated
treatment of cardiovascular disease, cannot be applied to the
general (‘healthy’) population, due to the high costs of diag-
nostic tools and pharmacological options.[9]
Recent findings seem to suggest the beneficial effects of
early interventions on ‘apparently healthy’ (asymptomatic) in-
dividuals, who may be nonetheless at potential risk of experi-
encingmajor cardiovascular events, due to clustering of various
cardiovascular risk factors or to the concomitant presence of
subclinical organ damage. These interventions need to be ap-
plied before the risk of these subjects becomes elevated. For
example, the TROPHY (TRial Of Preventing HYpertension)
study[10] has demonstrated the efficacy of treating subjects with
pre-hypertension, whereas other studies have shown the im-
portance of a therapeutic approach in patients with impaired
fasting glucose and insulin resistance,[11,12] and metabolic syn-
drome,[13-15] in terms of reduced incidence of hypertension, dia-
betes, obesity and dyslipidaemia. Although preliminary, these
results may be quite meaningful to design future preventive
strategies to reduce the burden of cardiovascular disease.
On the basis of these considerations, the BORDERLINE study
was designed as a pilot experience to investigate the prevalence of
values in the high-normal range (borderline) for different cardio-
vascular risk factors. Thus, the primary aim of this survey was to
identify the prevalence of ‘borderline’ conditions, i.e. patients with
pre-hypertension, overweight and early abnormalities in glucose
and lipid profiles, in the setting of general practice in Italy. This
article presents and discusses the main findings of this study.
Methods
Methodology of the Study
The BORDERLINE study represents a preliminary ex-
perience, designed to evaluate the prevalence of patients with
‘borderline’ values of cardiovascular risk factors among out-
patients followed by physicians operating in the setting of
general medicine in Italy.
The study conformed to the Declaration of Helsinki and its
subsequent modifications, and was approved by the reference
Ethical Committee of the participating physicians. The con-
fidentiality of the data was carefully and strictly protected.
Written consent to participate in the programme was obtained
by all involved physicians and patients. Confidentiality on
demographic and clinical data of individual patients was
carefully preserved.
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Physicians’ Recruitment
Physicians’ recruitment started in June 2009. Participants
involved in the present study were randomly selected, in order
to have a representative sample of the physicians in Italy, from
a community of medical doctors who shared the following
specific features: (i) experience in data collection and clinical
case report form (CRF) compilation; and (ii) a routine practice
of at least 60 patients per week, on average. Physicians involved
in this pilot study were distributed in three main areas
throughout the Italian territory (North, Centre and South).
Physicians were invited to participate in a pilot observational
study, aimed at evaluating prevalence of borderline cardio-
vascular risk factors in their outpatients’ population. Acceptance
of this initial invitation placed physicians under no obligation, and
physicians were entitled to drop out of the survey at any stage.
Written invitations were forwarded in a sizable number to
ensure a sufficient representation of the study population
sample, and to achieve this target within a period of approxi-
mately 3–4 weeks. Following their acceptance, involved phy-
sicians were asked to report clinical data, which were extracted
from their clinical records from the first 20 consecutive adult
Caucasian outpatients aged more than 30 years, whatever the
reason they referred to their own attending physicians. The
entire data collection was completed by participants on-site
and the completed CRFs were then delivered to the Data
Collection Centre by mail. At each study site, collection of data
was conducted during 1 week within 1 month during summer
2009. Physicians who completed the programme did not receive
any compensation for their participation.
The planned sample size of the survey participants included
about 60 physicians in order to achieve an adequate re-
presentation of all Italian regions, as well as to limit excessive
heterogeneity in age, gender, geographic location, professional
expertise and practice size. The predefined minimum percent-
age of responses to achieve in order to declare the representa-
tive sample size was arbitrarily fixed to 80% of the total sample.
Overall, the survey generated a population sample of 53 in-
dividual involved physicians (88.3% of the planned sample size)
and reflected approximately an outpatient practice of about 1000
patients per week. Patients included in the present analysis were
stratified in gender groups, according to the purpose of the study.
Data Collection
Data collection included full medical history and physical
examination, anthropometric and clinical parameters, con-
comitant cardiovascular risk factors, current therapy for hy-
pertension, lipid disorders, diabetes and other cardiovascular
diseases, as well as any concomitant medications.
Based on anthropometric data, calculation was made of
body mass index (BMI), which was expressed as bodyweight in
kilograms divided by body surface in square metres. Clinic
systolic and diastolic blood pressure (BP) levels, serum lipids,
blood glucose and glycosylated haemoglobin (HbA1c) levels,
when available, were extracted from available clinical records
and generally not exceeding 12 months.
Clinical data were collected in a specific CRF in which physi-
cians identified thresholds rather than reported absolute values
of major cardiovascular risk factors (see Supplemental Digital
Content 1, http://links.adisonline.com/HBZ/A2). All parameters
reported in the CRFs were derived from the clinical databases of
enrolled physicians, if available, and were not measured at the
time of the observation. Physicians were requested to report
clinical data not exceeding 6 months before the observation.
Data Analysis
Available data were centrally analysed. Normal and ab-
normal values of different clinic andmetabolic parameters were
reported in a separate addendum and indicated as thresholds in
the CRF. In particular, borderline values were considered as
follows: BP 130–140/85-90mmHg;[16] serum total cholesterol
180–200mg/dL;[16] low-density lipoprotein cholesterol (LDL-
C) 130–150mg/dL;[16] high-density lipoprotein cholesterol
(HDL-C) 30–40mg/dL in men and 40–50mg/dL in women;[17,18]
triglyceride levels 130–150mg/dL;[17,18] and fasting glucose
100–110mg/dL.[19,20]
Population with valuable clinical data
(n = 826)
Population included in the analysis
(n = 692)
Women (n = 377)Men (n = 315)
Population without history of CV events
and available for data analysis
(n = 692)
11 individuals excluded because
of missing or partial data
134 individuals excluded
due to CV event history
Overall population sample
(n = 837)
Fig. 1. Outpatients’ selection for the analysis. CV= cardiovascular.
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Statistical Analysis
All data were entered into Microsoft Access for Windows
(Microsoft Office, Microsoft Corp., Redmond, WA, USA).
Continuous variables were expressed as mean – standard
deviation and compared by a chi-square test. Discrete variables
were expressed as percentages and compared by Pearson’s chi-
squared test. Because of the relatively small sample size, the
comparisons were considered relevant for p < 0.05.
Results
Population Sample
As shown in figure 1, initially 53 Italian physicians reported
informationon837 individual outpatients.Among these, 11 (1.3%)
records were omitted from the analysis because of missing
or partial clinical data and 134 (16.2%) outpatients were ex-
cluded because of a history of previous cardiovascular events
(including coronary artery disease, stroke, peripheral artery
disease or heart failure or diagnosed organ damage, renal dis-
ease or cancer). Thus, a total population sample of 692 other-
wise healthy outpatients (377 women, mean age 60.9– 13.2 years,
BMI 26.6 – 5.0 kg/m2), which represents 83.7% of the origi-
nal population sample, was included in the present analysis.
General characteristics of the study population are reported in
table I.
Anthropometric and Clinical Parameters
No significant difference was found regarding age and BMI
between the two gender groups, although the men showed
significantly higher values of height, weight and waist cir-
cumference than the women (table I). In the overall population
sample, serum levels of both creatinine and uric acid were in the
normal range, showing no significant differences between the
two gender groups.
Analysis of ‘Borderline’ Values
The distribution of patients having normal, borderline and
abnormal values of clinical parameters considered for the pre-
sent analysis is reported in table II. The majority of individuals
showed normal BP levels (i.e. <130/85mmHg), both for the
systolic and for the diastolic BP levels (figure 2). Prevalence of
borderline systolic BP levels was at least comparable with those
within normal BP thresholds, while borderline diastolic BP lev-
els were significantly less reported than those within normal BP
thresholds (p < 0.05). As expected, the simultaneous detection
of systolic and diastolic BP levels in the high-normal range was
relatively uncommon in this population sample of otherwise
healthy subjects. Women showed a significantly higher pre-
valence of normal BP levels compared with men (p < 0.05),
whereas a significantly higher number of men showed border-
Table I. General characteristics of the study populationa
Parameter Overall
(n =692)
Men
(n = 315)
Women
(n= 377)
p-Value
(Fisher)
Age (y) 60.9– 13.2 60.8– 13.3 61.0– 13.2
Height (cm) 169.9–8.4 171.8–6.8 161.2– 6.3 <0.05
Weight (kg) 73.5– 15.0 79.7– 14.0 68.3– 13.8 <0.05
Waist circumference (cm) 96.9– 16.4 100.0–17.4 94.3– 15.1 <0.05
Body mass index (kg/m2) 26.6– 5.0 27.0– 4.4 26.3– 5.4
Smoking (%) 169 (24.4) 97 (30.8) 72 (19.1) <0.05
Family history of hypertension (n) 390 (56.4) 165 (52.4) 225 (59.7)
Family history of diabetes mellitus (n) 208 (30.1) 97 (30.8) 111 (29.4)
Hypertension (%) 411 (59.4) 203 (67.6) 208 (55.1) <0.05
Hypercholesterolaemia (%) 303 (43.8) 145 (46.0) 158 (41.9)
Diabetes (%) 129 (18.6) 72 (22.8) 57 (15.1) <0.05
Obesity (%) 117 (16.9) 52 (16.5) 65 (17.2) <0.05
Creatininaemia (mg/dL)b 1.0 –0.5 1.1 – 0.6 0.9 –0.5
Uric acid (mg/dL)b 4.6 –1.5 5.9 – 1.6 5.1 –1.1
a Data expressed as mean–SD. Numbers in parentheses are percentages by overall population.
b When available.
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line or abnormal BP values, both for the systolic and for the
diastolic BP thresholds.
About 40% of the patients showed high levels of total cho-
lesterol, while prevalence of values of total cholesterol in the
upper-normal range was comparable with that of normal
thresholds, and significantly lower than that of above-normal
levels of this parameter (figure 3), without any significant dif-
ference between gender groups. In contrast, the majority of the
patients showed normal values of LDL-C, followed by those
having borderline and abnormal values of this parameter. In
particular, borderline levels for LDL-C were reported in a
significantly lower proportion of patients compared with nor-
mal levels and in a significantly higher proportion of patients
having abnormal values of these parameters.
A significantly higher proportion of individuals of both
genders had normal levels of both HDL-C and triglycerides
compared with those who had borderline or abnormal levels of
these parameters, as shown in figure 4. It should also be noted,
however, that a significantly higher prevalence of borderline
levels for HDL-C compared with that of above-normal levels
Table II. Absolute prevalence and percentage of normal, above-normal (‘borderline’) and abnormal thresholds for all clinical parameters considered in
the analysisa
Thresholds Overall
(n= 692)
p-Value (chi-square) Men
(n = 315)
Women
(n= 377)
p-Value
(Fisher)
SBP levels (mmHg)
<130 305 (44.1) 124 (39.4) 181 (48.0) <0.05
130–140 278 (40.2) 137 (43.5) 141 (37.4) <0.05
>140 91 (13.2) 49 (15.6) 42 (11.1) <0.05
DBP levels (mmHg)
<85 422 (61.0) <0.01 170 (54.0) 252 (66.8) <0.05
85–90 206 (29.8) 110 (34.9) 96 (25.5) <0.05
>90 45 (6.5) 30 (9.5) 15 (4.0) <0.05
Total cholesterol levels (mg/dL)
<180 176 (25.7) <0.01 90 (28.6) 88 (23.3)
180–200 193 (27.9) 83 (26.3) 110 (29.2)
>200 271 (39.2) 122 (38.7) 149 (39.5)
LDL-C levels (mg/dL)
<130 292 (42.2) <0.01 140 (44.4) 152 (40.3)
130–150 162 (23.4) 66 (21.0) 96 (25.5) <0.05
>150 117 (16.9) 60 (19.0) 57 (15.1) <0.05
HDL-C levels (mg/dL)
Men >40; women >50 405 (58.5) <0.01 174 (55.2) 231 (61.3) <0.05
Men 30–40; women 40–50 200 (28.9) 101 (32.1) 99 (26.3) <0.05
Men <30; women <40 20 (2.9) 14 (4.4) 6 (1.6) <0.05
Triglycerides levels (mg/dL)
<130 306 (44.2) <0.01 131 (41.6) 175 (46.4)
130–150 165 (23.8) 74 (23.5) 91 (24.1)
>150 146 (21.1) 82 (26.0) 64 (17.0) <0.05
Fasting glucose levels (mg/dL)
<100 382 (55.2) <0.01 155 (49.2) 227 (60.2) <0.05
100–110 130 (18.2) 70 (22.2) 60 (15.9) <0.05
>110 99 (14.3) 55 (17.5) 44 (11.7) <0.05
a Numbers in parentheses are percentages by overall population.
DBP= diastolic blood pressure; HDL-C= high-density lipoprotein cholesterol; LDL-C= low-density lipoprotein cholesterol; SBP= systolic blood pressure.
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was reported both for both men and women, whereas no sig-
nificant difference was found between these two categories with
respect to triglyceride levels.
Finally, a significantly higher proportion of individuals,mostly
women, had normal fasting glucose levels, compared with that
having borderline values of glucose profile. No significant dif-
ference was found between borderline and abnormal glucose
thresholds, both in men and women, as shown in figure 5.
A similar prevalence of subjects having normal or high-normal
BMI (overweight) was found, which was significantly higher
than that of subjects with high values of BMI. In particular,
a significantly higher proportion of men showed borderline
values of BMI than that reported in women, who were signif-
icantly more prevalent in the normal thresholds of BMI.
Discussion
The present manuscript reports the analysis of a pilot ob-
servational study, performed in Italy, in the setting of daily
clinical practice. The primary aim of this study was to collect
information on the prevalence of high-normal (‘borderline’)
levels of major cardiovascular factors in outpatients followed
by general practitioners in Italy. The results of this analysis are
somehow surprising and unexpected, since they demonstrated
a relatively high prevalence of borderline values of cardio-
vascular risk factors, whichwas at least comparable with that of
normal, but significantly higher than that of abnormal thresh-
olds in a cohort of otherwise healthy subjects in Italy. Among
the numerous data made available by this analysis, some spe-
cific aspects deserve discussion.
First, to our knowledge, this is the first experience primarily
designed to evaluate the prevalence of borderline abnormalities
of major cardiovascular and metabolic risk factors in a setting
of general clinical practice. Similar data, in fact, have been
provided by the Progetto Cuore[21] of the Italian Ministry of
Health, which analysed prevalence and absolute levels of major
cardiovascular and metabolic risk factors in a much larger rep-
resentative sample of the Italian general population, thus pro-
viding information of both borderline and above-normal values
of the same clinical parameters and other clinical and pop-
ulation items. This analysis, however, was based on clinical
data derived from individuals of both sexes, aged between
35 and 74 years, who were examined between 1998 and 2002.
Our analysis, although limited to a smaller population sample
than that included in the Progetto Cuore,[21] can be considered
more up to date and more focused on subjects with borderline
abnormalities of different clinical parameters relevant to
cardiovascular risk. In this latter regard, it should also be
mentioned that the normal and abnormal thresholds applied in
the Progetto Cuore[21] are frankly higher than those used in our
analysis, which strictly reflects the most recent guidelines for
the diagnosis and treatment of hypertension,[16] lipid[17,18] and
glucose[19,20] abnormalities. For example, in the Progetto
Cuore[21] arterial hypertension was defined as systolic and/or
diastolic BP levels above 160/95mmHg (borderline BP levels:
140–159/90–94mmHg), while hypercholesterolaemia was de-
fined as serum total cholesterol levels above 240mg/dL (bor-
derline total cholesterol: 200–239mg/dL). These thresholds
have been substantially modified in the most recent guidelines.
These differences in the diagnostic criteria may at least, in part,
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explain the lower prevalence of individuals showing borderline
levels of BP (19% in men and 14% in women) in the Progetto
Cuore[21] than those reported in our analysis (43.5% in men and
37.4% in women for the systolic BP, and 34.9% in men and
25.5% in women for the diastolic BP levels). The same differ-
ences can be observed for those subjects showing abnormal
glucose profile; this proportion was lower in the Progetto
Cuore[21] (8% in men and in 4% women, taking 110–126mg/dL
as reference values) than in our analysis (22.2% in men and
15.9% in women, considering 100–110mg/dL as reference val-
ues). On the other hand, our findings are confident with the
results of a recent meta-survey of observational studies per-
formed in Italy, which reported a significantly higher propor-
tion of elevated values of systolic BPwith respect to elevation of
diastolic BP levels in the setting of general medicine. A similar
prevalence of diabetes and hypercholesterolaemia was re-
ported, although this referred to hypertensive patients followed
in different clinical settings rather than to outpatients followed
by general practitioners as in the present investigation.[22]
A second aspect that is of particular relevance is the un-
expectedly and relatively high prevalence of individuals with
borderline values of major cardiovascular and metabolic risk
factors compared with those having normal values of these
parameters in a setting of an otherwise healthy general pop-
ulation. In our analysis, in fact, prevalence of individuals hav-
ing borderline systolic BP levels was comparable with that of
subjects showing normal systolic BP levels, but significantly
more prevalent than those with abnormal systolic BP levels (i.e.
hypertensive patients), with these differences being more evi-
dent in men than in women. The same trends were observed for
diastolic BP levels, LDL-C, HDL-C and BMI values. These
aspects may at least, in part, contribute to explain the relatively
higher risk of developing major CV events, including myo-
cardial infarction, stroke and CV death, observed in the general
population of asymptomatic individuals than that reported in
those patients with previous history of (symptomatic) heart or
vascular disease.[23] In this view, our results are consistent with
several recommendations of current international guidelines,
which promote a closer scrutiny for global cardiovascular risk
stratification, in order to early identify and promptly treat those
(asymptomatic) subjects at potentially high cardiovascular risk
before the occurrence of major cardiovascular events.[16,24]
A third aspect that is of particular relevance is the distribu-
tion of individuals with abnormal lipid profile. While only a
minority of the subjects showed abnormal LDL-C levels, about
one-third of the population had borderline values of HDL-C
and triglycerides. By adding these abnormal parameters to
high-normal BP levels (about 35–40%), impaired glucose reg-
ulation (about 20%) and overweight (about 41%), and con-
sidering the average value of waist circumference (about 97 cm),
we can reasonably estimate that about 30–35% of total popula-
tion sample included in our analysis may have had a metabolic
syndrome, according to current diagnostic criteria.[17,18] This
condition may significantly increase not only the risk of devel-
oping major cardiovascular events, but mostly the 5–10 year risk
of new-onset diabetes.[25] Thus, our results suggest closer attention
to identifying those subjects having metabolic syndrome, in order
to reduce their cardiovascular and metabolic risk.
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A final aspect that deserves to be discussed is the relatively
high prevalence of subjects with abnormal glucose regulation.
This condition, which includes two clinical settings, i.e. fasting
hyperglycaemia (IFG) and impaired glucose tolerance (IGT),
may be considered as intermediate stages between normal
glucose homeostasis and diabetes. Although in our analysis we
only considered fasting glucose levels to define subjects with
normal, borderline or abnormal glucose profile, several reports
indicated that the prevalence of IFG and IGT (or both) ac-
counted for 20% of the general adult population,[26] which was
comparable with that observed in our population (about 20%).
The considerable prevalence of this condition may be of par-
ticular interest, because within 3–5 years about 25% of subjects
with abnormal glucose regulation may develop diabetes, 50%
continue to have an abnormal glucose profile, while the re-
maining 25% may regress to a normal glucose tolerance.[27]
Conclusions
There is a close, linear relationship between normal, bor-
derline and abnormal values of cardiovascular and metabolic
risk factors and increased incidence of cardiovascular diseases.
While it is widely accepted that the presence of hypertension,
hypercholesterolaemia, obesity and diabetes significantly in-
creases cardiovascular morbidity and mortality, it has been
recently demonstrated that even levels below those thresholds
traditionally considered for the diagnosis of these clinical
conditions, i.e. borderline values, are associated with a signif-
icantly higher cardiovascular risk compared with that reported
in the normal range of these parameters. In the general pop-
ulation, in fact, a linear relationship between BP, total choles-
terol and LDL-C, BMI, glucose levels and cardiovascular
complications has been described, and these associations ap-
peared to be even more significant when these abnormalities
clustered in the same individuals.
Our results demonstrate a relatively high prevalence of bor-
derline values ofmajor cardiovascular risk factors, which is at least
comparablewith that of normal thresholds, but higher than that of
abnormal values in the setting of general practice in Italy. Since
early and effective interventions on major cardiovascular risk
factors have demonstrated a favourable influence on cardio-
vascular disease outcomes, our findings may have a potential im-
pact for future prevention strategies for reducing the overall
burden of cardiovascular disease in Italy, by targeting diag-
nostic and therapeutic interventions to those asymptomatic
individuals with borderline abnormalities of cardiovascular
risk profile, who are at increased risk of developing major
cardiovascular events.
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